Videos
This Week in Managed Care: August 9, 2019
August 9th 2019This week, the top managed care stories included CMS giving chimeric antigen receptor T-cell payments a boost; a US task force announcing that those at risk for pancreatic cancer should be screened; FDA revealing Novartis withheld data about a high-cost gene therapy.
Dr. Chao on Minimal Residual Disease in ALL
August 9th 2019Nelson Jen An Chao, MD, professor of medicine, Donald D. and Elizabeth G. Cooke Cancer Research Professor, chief, Division of Cell Therapy in the Department of Medicine, Duke Cancer Institute, discusses minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL).
Dr. Mei on Investigational CAR T-Cell Therapies and Antibody-Drug Conjugates in Hodgkin Lymphoma
August 5th 2019Matthew G. Mei, MD, assistant clinical professor, Department of Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses investigational CAR T-cell therapies and antibody-drug conjugates (ADCs) in Hodgkin lymphoma.
Dr. Rischin on KEYNOTE-048 Results in Head and Neck Squamous Cell Carcinoma
August 1st 2019Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the phase III KEYNOTE-048 trial, which examines pembrolizumab or pembrolizumab plus chemotherapy versus EXTREME as first-line therapy for patients with recurrent/metastatic head and neck squamous cell carcinoma.
Dr. Sehgal on the Clinical Implications of CAR T-Cell Therapy in DLBCL
July 30th 2019Alison R. Sehgal, MD, assistant professor of medicine, hematologist/medical oncologist, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the clinical implications of CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).
Dr. Hou on the Latest Updates With CAR T-Cell Therapy in DLBCL
July 19th 2019Jing-Zhou Hou, MD, PhD, co-chair of the Hematological Malignancies program, and medical oncologist, hematologist, and clinical instructor at University of Pittsburgh Medical Center Hillman Cancer Center, discusses the latest updates with CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).
Dr. Karmali on Next Steps of Research Regarding Ibrutinib Maintenance in MCL
July 12th 2019Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the next steps for research regarding the use of ibrutinib (Imbruvica) as maintenance therapy in mantle cell lymphoma (MCL).
Dr. McCulloch on the Use of R-BAC in MCL After Progression on BTK Therapy
July 11th 2019Rory McCulloch, MD, vice chair, South West Peninsula, HaemSTAR, hematology registrar, University Hospitals, Plymouth, discusses the use of R-BAC (rituximab [Rituxan],bendamustine, and cytarabine) in patients with mantle cell lymphoma (MCL) who had progressed on initial therapy with a BTK inhibitor.
Dr. Sehgal on Managing CRS and Neurotoxicity From CAR T-Cell Therapy
July 9th 2019Alison R. Sehgal, MD, assistant professor of medicine, hematologist/medical oncologist, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses ways to manage cytokine release syndrome (CRS) and neurotoxicity associated with CAR T-cell therapy.
Dr. Meric-Bernstam on the Activity of Telaglenastat and Cabozantinib in mRCC
July 9th 2019Funda Meric-Bernstam, MD, chair of the Department of Investigational Cancer Therapeutics, medical director of the Institute for Personalized Cancer Therapy, and a professor in the Divisions of Cancer Medicine and Surgery at The University of Texas MD Anderson Cancer Center, discusses the activity of the combination of telaglenastat (CB-839) and cabozantinib (Cabometyx) in heavily pretreated patients with metastatic renal cell carcinoma (mRCC).
Dr. Karmali on the Toxicity Profile of Ibrutinib Maintenance in MCL
July 4th 2019Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the toxicity profile of ibrutinib (Imbruvica) maintenance therapy after induction therapy in patients with mantle cell lymphoma (MCL).
Dr. Shadman on Challenges With CAR T-Cell Therapy
June 28th 2019Mazyar Shadman, MD, MPH, assistant member, Fred Hutchinson Cancer Research Center, assistant professor, Medical Oncology Division, Department of Medicine, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses challenges with CAR T-cell therapy.
Dr. Siddiqi on CAR T-Cell Therapy in Relapsed/Refractory CLL/SLL
June 21st 2019Tanya Siddiqi, MD, a hematologist/oncologist at City of Hope, discusses the phase I/II TRANSCEND CLL 004 trial, which evaluated the efficacy of anti-CD19 CAR T cells in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Dr. Davids on the Use of CAR T-Cell Therapy in CLL
June 18th 2019Matthew S. Davids, MD, MMSc, associate director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses the use of CAR T-cell therapy for the treatment of patients with chronic lymphocytic leukemia (CLL).
Dr. Lin on Combination Atezolizumab and Chemoradiation in Locally Advanced NSCLC
June 10th 2019Cancer Network spoke with Steven H. Lin, MD, PhD, of MD Anderson Cancer Center, on the findings of a phase II trial of atezolizumab plus chemoradiation therapy in locally advanced non-small-cell lung cancer.
